Article

Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirement

2023-08-21

Abstract excerpt

<h4>Background: </h4> & Objective Covid-19 disease is implicated in increased mortality among immunocompromised patients. The JAK inhibitor, baricitinib (bar), or the IL-6 inhibitor, tocilizumab (toc), demonstrated a survival benefit in patients with severe disease. However, evidence supporting their use in immunocompromised patients with severe Covid-19 is scarce. We aimed to assess clinical outcomes of bar/toc t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6245a154-e24f-5227-b2d6-acc6aa0508f8
DOI: 10.21203/rs.3.rs-3228936/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical outcomes of immunomodulation therapy in immunocompromised patients with severe Covid-19 and high oxygen requirementDOI 10.21203/rs.3.rs-3228936/v1Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational studySemantic proximity Read

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort StudySemantic proximity Read

The efficacy and safety of monoclonal antibody treatments against COVID-19: A systematic review and meta-analysis of randomized clinical trialsSemantic proximity Read

REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity Read

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialSemantic proximity Read

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.Semantic proximity Read

Unveiling Protection: A Meta-Analysis of Tixagevimab-Cilgavimab Prophylaxis in 28,950 Transplant Recipients and Immunocompromised Patients Against COVID-19Semantic proximity Read